HC Wainwright Has Pessimistic Outlook of VRDN Q2 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) – Research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Viridian Therapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst D. Tsao now a…

Read Full Article →